Malignant conversion is the stage of cancer progression during which tumorigenic cells acquire the capacity for invasion and metastasis. The identification of gene products involved in this process is a central aim in the field of molecular carcinogenesis (7). Recently, a number of excellent new systems have been developed in which malignant conversion can be studied at the molecular level. These systems include transfection of Ha-ras family oncogenes into fibroblasts (2) and human bronchial epithelial cells (1,3) , transfection of the fos oncogene into murine squamous papilloma cells that contain an activated c-Ha-ras gene (4), and repeated treatment of mouse skin with carcinogens (5). The article by Bonfil and co-workers in this issue of the journal (3) describes a new model: v-Ha-ras-transfected human bronchial epithelial cells xenotransplanted in de-epithelialized rat tracheas implanted in nude mice. A striking finding in all of these model systems is the correlation of an increased expression of extracellular matrix-degrading metalloproteinases with the acquisition of the malignant phenotype (2, 3, 5, 6) . This finding raises the question of the potential causal role of metalloproteinases in this critical stage of cancer progression.
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At least two metalloproteinases have been implicated in malignant conversion. These are type IV collagenase (2, 3, 7) and transin (5) . They are distinct members of a family of metalloproteinases (8,9) (table 1). All of these enzymes are hydrolases that are active at neutral pH and that require a metal ion such as Ca 2+ or Zn 2+ for activity. The other members of the metalloproteinase family have not been thoroughly studied for potential correlation with malignant conversion. Only a subset of the members of the metalloproteinase family has been cloned and sequenced to date. Therefore, characterization of additional metalloproteinases and their potential correlation with stages of cancer progression are important areas of future research.
Regulation of metalloproteinase transcription may not be sufficient to effect extracellular enzyme activity, because a characteristic of the metalloproteinases is that they are secreted in a latent zymogen form and require activation to cleave their preferred substrates. Activation can occur following treatment in vitro with proteinases, such as trypsin and plasmin, or by exposure to organomercurial compounds (10) (11) (12) . In the latter case, activation involves a conformational change and results in the autocatalytic removal of an amino terminal peptide from the latent proenzyme ( fig. 1) , with a corresponding reduction in molecular mass. Cleavage of the amino terminal peptide occurs at a specific locus adjacent to a highly conserved sequence, PRCGVPDV, containing an unpaired cysteine residue ( fig. 1 ). This sequence may play an important role in the mechanism of activation (10, 11) . In contrast to in vitro studies, the in vivo mechanism of activation of the metalloproteinases is only a matter of speculation. Clarification of in vivo activation is crucial for a meaningful understanding of the potential functional role of these enzymes in tumor cell invasion. In this regard, Bonfil et al. (3) showed an increase in the amount of mRNA for the latent type IV procollagenase as well as an increase in the amount of active enzyme in the conditioned media of invasive and metastatic cells. These results suggest that both increased expression and increased activation of latent enzyme accompany malignant conversion in this system. Modulation of metalloproteinase function after secretion can take place at many levels, including activation of the latent enzyme, cell surface binding, substrate binding, and interaction with host-or tumor cell-derived metalloproteinase inhibitors. An important inhibitor is a secreted protein called TIMP (tissue inhibitor of metalloproteinases) (13). In regard to metalloproteinases and the malignant process, TIMP can be considered within the class of tumor-suppressor gene products, inasmuch as elevated expression of TIMP by a tumor cell may block the activity of metalloproteinases secreted by the same cell. In startling support of this concept, transfection of TIMP antisense RNA into Swiss 3T3 cells, resulting in reduction of TIMP levels, was reported to confer oncogenicity and metastatic propensity (13).
If metalloproteinases directly facilitate malignant conversion, the mechanism of action may involve disruption of basement membranes or interstitial stroma (7), thereby augmenting tumor cell invasion of these extracellular matrix bar-Flgnre 1. Activation scheme for matrix metaUoproteinases. Type IV procoUagenase, interstitial procoUagenase, and prostroraelysin are represented diagrammatically and are aligned to show regions of protein-sequence homology. MBD: putative metal ion-binding domain. Type IV procoUagenase contains a cysteine-rich domain that shows homology to fibronectin; however, this cysteine-rich domain is absent from procoUagenase and prostromelysin. Upon treatment with organomercurial compounds in vitro, aU three enzymes are activated with a concomitant removal of an amino terminal segment of the latent enzyme. The removed segment contains an unpaired cysteine residue within the conserved amino acid sequence PRCGVPDV adjacent to the proenzyme cleavage site (10) . Studies on site-directed mutagenesis have shown that alterations in this sequence result in spontaneous activation of transin, the rat homologue of stromelysin (/ /) . This sequence may play a central role in the in vivo activation of these metalloproteinases.
riers. However, it is likely that metalloproteinases also play a role in other aspects of the normal phenotype and the malignant phenotype (e.g., differentiation, growth, motility, and angiogenesis). Transfection of metalloproteinase genes may not be sufficient for examination of their role in invasion and metastasis, because the recipient cell might lack other genes necessary for the full malignant phenotype. Therefore, direct proof of the causal role of metalloproteinases during in vivo malignant conversion awaits transfection of metalloproteinase antisense mRNA into suitable recipient cells. The model systems such as those developed by Bonfil et al. offer an exciting means to conduct these important experiments.
